Ixazomib (Ninlaro)
On February 8th, 2016
On November 20, 2015, the U.S. Food and Drug Administration approved ixazomib (NINLARO, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is the first approved oral proteasome inhibitor.
Full prescribing information is available at:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf
On November 20, 2015, the U.S. Food and Drug Administration approved ixazomib (NINLARO, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is the first approved oral proteasome inhibitor.
Full prescribing information is available at:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf
No comments have been posted yet.